Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
You might want to recommend this clinical trial to your patients with metastatic melanoma which evaluates whether preparatory chemotherapy followed by infusion of DMF5 cells is a safe and effective for shrinking melanoma tumors.
Study Type: InterventionalAge/Sex Requirement: 18 years+ (None)
Sponsor: National Cancer Institute
ClinicalTrials.gov Identifier: NCT00924001
Purpose: To determine whether preparatory chemotherapy followed by infusion of DMF5 cells is a safe and effective for shrinking melanoma tumors. The primary outcomes measure is clinical response according to RECIST criteria and toxicity. The secondary outcomes measure is the rate of repopulation of young TIL cells as well as correlates that predict in vivo persistence and clinical response.
